Youngil Koh

16.7k total citations
143 papers, 1.7k citations indexed

About

Youngil Koh is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Youngil Koh has authored 143 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 73 papers in Hematology, 56 papers in Oncology and 51 papers in Molecular Biology. Recurrent topics in Youngil Koh's work include Multiple Myeloma Research and Treatments (49 papers), Peptidase Inhibition and Analysis (19 papers) and Protein Degradation and Inhibitors (18 papers). Youngil Koh is often cited by papers focused on Multiple Myeloma Research and Treatments (49 papers), Peptidase Inhibition and Analysis (19 papers) and Protein Degradation and Inhibitors (18 papers). Youngil Koh collaborates with scholars based in South Korea, United States and Puerto Rico. Youngil Koh's co-authors include Sung‐Soo Yoon, Eunhyek Joa, Kyongsu Yi, Se‐Hoon Lee, Dae Seog Heo, Doo Hyun Chung, Ja Min Byun, Kil‐Soo Kim, Seung‐Hoon Lee and Tae Min Kim and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

Youngil Koh

131 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Youngil Koh South Korea 21 729 675 546 353 211 143 1.7k
George Z. Cheng United States 24 750 1.0× 1.4k 2.1× 536 1.0× 108 0.3× 397 1.9× 67 2.6k
Satoshi Hara Japan 24 571 0.8× 472 0.7× 542 1.0× 74 0.2× 86 0.4× 210 2.1k
Luca Mazzarella Italy 22 712 1.0× 797 1.2× 274 0.5× 164 0.5× 409 1.9× 90 1.8k
Koichiro Muta Japan 19 318 0.4× 505 0.7× 51 0.1× 284 0.8× 231 1.1× 66 1.6k
Yanming Zhang United States 23 571 0.8× 932 1.4× 280 0.5× 494 1.4× 249 1.2× 148 2.0k
Huilai Zhang China 23 727 1.0× 581 0.9× 158 0.3× 89 0.3× 221 1.0× 159 1.8k
Matthew J. Barth United States 18 548 0.8× 304 0.5× 144 0.3× 86 0.2× 61 0.3× 72 1.2k
Jian Qi Australia 19 285 0.4× 585 0.9× 124 0.2× 181 0.5× 42 0.2× 51 2.7k
Longhua Chen China 27 516 0.7× 1.5k 2.2× 451 0.8× 28 0.1× 1.0k 4.9× 120 2.5k
Qian Kang China 20 242 0.3× 683 1.0× 135 0.2× 111 0.3× 282 1.3× 77 1.7k

Countries citing papers authored by Youngil Koh

Since Specialization
Citations

This map shows the geographic impact of Youngil Koh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Youngil Koh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Youngil Koh more than expected).

Fields of papers citing papers by Youngil Koh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Youngil Koh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Youngil Koh. The network helps show where Youngil Koh may publish in the future.

Co-authorship network of co-authors of Youngil Koh

This figure shows the co-authorship network connecting the top 25 collaborators of Youngil Koh. A scholar is included among the top collaborators of Youngil Koh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Youngil Koh. Youngil Koh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Kong, Jee Hyun, Junshik Hong, Ja Min Byun, et al.. (2025). Azacitidine followed by R-GDP in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma: preliminary results from a multicenter, phase II study. Therapeutic Advances in Hematology. 16. 1584267121–1584267121. 2 indexed citations
3.
Byun, Ja Min, Sung‐Soo Park, Seung Pil Jung, et al.. (2024). Efficacy and Safety of Bispecific T-Cell Engagers in Relapsed/Refractory Multiple Myeloma: A Real-World Data-Based Case-Controlled Study. Transplantation and Cellular Therapy. 31(2). 74.e1–74.e11. 1 indexed citations
4.
Park, Changhee, Ho Sup Lee, Ka‐Won Kang, et al.. (2024). Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial. Nature Communications. 15(1). 2776–2776. 6 indexed citations
5.
Kim, Seokhyeon, Ja Min Byun, Junshik Hong, et al.. (2024). Phase II trial of imatinib mesylate in patients with PDGFRA/B ‐negative hypereosinophilic syndrome. British Journal of Haematology. 205(6). 2305–2314. 2 indexed citations
6.
Kim, Sheehyun, Ja Min Byun, Youngil Koh, et al.. (2024). Pursuing dynamics of minimal residual leukemic subclones in relapsed and refractory acute myeloid leukemia during conventional therapy. Cancer Medicine. 13(7). e7182–e7182. 1 indexed citations
7.
Park, Mi-Young, Dongho Kim, Ja Min Byun, et al.. (2024). Genetic Risk Factors for Bortezomib-induced Neuropathic Pain in an Asian Population: A Genome-wide Association Study in South Korea. Journal of Pain. 25(9). 104552–104552.
8.
Woo, Kyung Ah, Han‐Joon Kim, Jung Hwan Shin, et al.. (2024). Parkinson’s disease is associated with clonal hematopoiesis with TET2 mutation. npj Parkinson s Disease. 10(1). 168–168. 3 indexed citations
9.
Yun, Jae Kwang, Sugyeong Kim, Geun Dong Lee, et al.. (2023). Pre-operative clonal hematopoiesis is related to adverse outcome in lung cancer after adjuvant therapy. Genome Medicine. 15(1). 111–111. 6 indexed citations
10.
Lee, Young-Ho, Xinxin Wang, Oded Singer, et al.. (2021). PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells. Molecular Therapy. 30(2). 579–592. 55 indexed citations
11.
Lee, Soon‐Tae, Ja Min Byun, Junshik Hong, et al.. (2020). High Cell-Free DNA Levels in Cerebrospinal Fluid Predict Leptomeningeal Seeding of Hematologic Malignancy. Journal of Clinical Neurology. 16(4). 581–581. 3 indexed citations
12.
Shin, Dong Hoon, Chang Kyung Kang, Jieun Park, et al.. (2020). Risk factors for and clinical outcomes of carbapenem non-susceptible gram negative bacilli bacteremia in patients with acute myelogenous leukemia. BMC Infectious Diseases. 20(1). 404–404. 11 indexed citations
13.
Kim, Inho, et al.. (2019). The importance of physical function in patients with multiple myeloma for improving quality of life. Supportive Care in Cancer. 28(5). 2361–2367. 6 indexed citations
14.
Han, Dohyun, Ji‐Won Kim, Youngil Koh, et al.. (2018). Plasma-based protein biomarkers can predict the risk of acute graft-versus-host disease and non-relapse mortality in patients undergoing allogeneic hematopoietic stem cell transplantation. Blood Cells Molecules and Diseases. 74. 5–12. 7 indexed citations
15.
16.
Suh, Hyeon Jeong, Seo Hyun Yoon, Kyung‐Sang Yu, et al.. (2018). The Genetic Polymorphism UGT1A4*3 Is Associated with Low Posaconazole Plasma Concentrations in Hematological Malignancy Patients Receiving the Oral Suspension. Antimicrobial Agents and Chemotherapy. 62(7). 20 indexed citations
17.
Suh, Hyeon Jeong, Inho Kim, Joo‐Youn Cho, et al.. (2017). Comparison of Plasma Concentrations of Posaconazole with the Oral Suspension and Tablet in Korean Patients with Hematologic Malignancies. Infection and Chemotherapy. 49(2). 135–135. 11 indexed citations
18.
Byun, Ja Min, et al.. (2017). Clinical Features and Outcomes of Light-Chain Dominant Multiple Myeloma: A Population-Based Study. Blood. 130. 5360. 1 indexed citations
19.
Park, Wan Beom, Joo‐Youn Cho, Eun Jung Kim, et al.. (2016). Effectiveness of increasing the frequency of posaconazole syrup administration to achieve optimal plasma concentrations in patients with haematological malignancy. International Journal of Antimicrobial Agents. 48(1). 106–110. 14 indexed citations
20.
Koh, Youngil, et al.. (2014). Establishment of Cell Lines from Both Myeloma Bone Marrow and Plasmacytoma: SNU_MM1393_BM and SNU_MM1393_SC from a Single Patient. BioMed Research International. 2014. 1–8. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by George Z. Cheng Breakdown of academic impact, for papers by Satoshi Hara Breakdown of academic impact, for papers by Luca Mazzarella Breakdown of academic impact, for papers by Koichiro Muta Breakdown of academic impact, for papers by Yanming Zhang Breakdown of academic impact, for papers by Huilai Zhang Breakdown of academic impact, for papers by Matthew J. Barth Breakdown of academic impact, for papers by Jian Qi Breakdown of academic impact, for papers by Longhua Chen Breakdown of academic impact, for papers by Qian Kang
Rankless by CCL
2026